Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts.
BACKGROUND
One major challenge to human cancer gene therapy, is efficient delivery of the gene-vector complex.


RESULTS
Using two distinct human nasopharyngeal carcinoma (NPC) models, we demonstrate that intra-tumoural (IT) administration of adenoviral-mediated wild-type p53 gene therapy (Ad-p53) caused no greater inhibition of tumour growth as compared to ionizing radiation (XRT) alone. Detailed histologic examination of tumour sections demonstrated that <15% of tumour cells were transduced by IT adv-beta-gal.


CONCLUSIONS
This report underscores the importance of developing gene transfer vectors, which can provide therapeutic levels of transgene expression efficiently in solid tumours.
Lax
S A
SA
Division of Experimental Therapeutics, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
Chia
M C
MC
Busson
P
P
Klamut
H J
HJ
Liu
F F
FF
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009303:Nasopharyngeal Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D014183:Transplantation, Heterologous